Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

Illumina, Inc.. (9/7/17). "Press Release: Illumina Files New Patent Infringement Suit Against Premaitha Health plc". San Diego, CA.

Region Region United Kingdom (GB)
Organisations Organisation Illumina Inc. (Nasdaq: ILMN)
  Group Illumina (Group)
  Organisation 2 Premaitha Health plc (AIM: NIPT)
  Group Premaitha Health (Group)
Products Product IONA® Test (genomic prenatal maternal blood test)
  Product 2 DNA sequencing technology
Persons Person Chambers, Rebecca (Illumina 201602 Investor Relations)
  Person 2 Endicott, Eric (Illumina 201310– Director Global Public Relations before Agilent 201204 Global PR Manager)
     


Illumina, Inc. (NASDAQ:ILMN) announced today that the company has filed a new patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief.

The new suit accuses Premaitha’s IONA® Test of infringing European Patent (UK) 1 524 321 B2 titled, “Non-invasive Detection of Fetal Genetic Traits,” which is exclusively licensed to Illumina from Sequenom, Inc.

Illumina and its wholly owned subsidiary, Verinata Health, Inc., previously filed suits in the UK against Premaitha accusing its Iona test of infringing European Patent (UK) 0 994 963 B2, European Patent (UK) 1 981 995 B1, European Patent (UK) 2 183 693 B1, European Patent (UK) 2 385 143 B1 and European Patent (UK) 2 514 842 B1. Those suits remain pending.


About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.


Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
ir@illumina.com
or
Media:
Eric Endicott, 858-882-6822
pr@illumina.com

   
Record changed: 2018-09-19

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Illumina (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top